碘芬布酸 | 554-24-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 碘芬布酸
• 英文名称: 2-(2,4,6-triiodo-phenoxy)-butyric acid
• 英文别名: 2-(2,4,6-Trijod-phenoxy)-buttersaeure；α-(2,4,6-triiodophenoxy)-butyric acid；α-(2,4,6-Trijodphenoxy)-buttersaeure；2-(2.4.6-Triiod-phenoxy)-buttersaeure；phenobutiodil；2-(2,4,6-triiodophenoxy)butanoic acid
• CAS: 554-24-5
• 化学式: C₁₀H₉I₃O₃
• 分子量: 557.893
• InChiKey: VYAGDYWTCWDKIS-UHFFFAOYSA-N

物化性质

• 熔点：
  124-125°

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  碘芬布酸 、 2,2,2-三氯乙醇 生成 2,2,2-trichloroethyl 2-(2,4,6-triiodophenoxy)butanoate
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  苯酚 在 甲醇 、 碘 、 chloroamine-T 、 potassium carbonate 、 丙酮 作用下， 生成 碘芬布酸
  参考文献：
  名称：

  Röntgenkontrastmittel auf der Basis jodierter Phenoxyfettsäuren

  摘要：

  Die Darstellung mono-, di-, tri- und tetrajodierter Phenoxyfettsäuren durch Kondensation jodierter Phenole mit geeigneten Halogenfettsäureestern oder durch Jodieren von Phenoxyfettsäuren mit JCL wird beschrieben。Bessere Herstellungsmethoden bekannter Jodphenole und die Synthesen einiger di-, tri- und tetrajodierter Phenole werden angegeben。Zwei Versuche zur Gewinnung der Tetrajod-m-aminobenzoesäure

  DOI：

  10.1002/ardp.19592921102

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound
  申请人：MALLINCKRODT, INC.(a Missouri corporation)

  公开号：EP0165630A2

  公开（公告）日：1985-12-27

  The invention relates to a method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radio-iodinated aromatic or heteroaromatic compound, in which the (hetero)aromatic nucleus optionally comprises one or more additional substituents, by reacting the corresponding halogenated or diazonium-substituted compound in the presence of a water-soluble acid and of copper ions as a catalyst with a likewise water-soluble chloride, bromide radiobromide, iodide or radio-iodide, in which the reaction is carried out in the presence of one or more reduction agents, which are stable in acid medium, in a quantity exceeding the quantity of catalyst. The invention also relates to a composition suitable for diagnostic examination and to a kit for the preparation thereof. The invention further relates to a method and an equipment for the preparation of said composition.

  本发明涉及一种制备氯化、溴化、放射性溴化、碘化和/或放射性碘化芳香族或杂芳香族化合物的方法，其中（杂）芳香族核可选择地包括一个或多个附加取代基、在水溶性酸和作为催化剂的铜离子存在下，使相应的卤代或重氮代化合物与同样的水溶性氯化物、溴化物、放射性溴化物、碘化物或放射性碘化物反应，其中反应是在一种或多种在酸介质中稳定的还原剂存在下进行的，还原剂的数量超过催化剂的数量。本发明还涉及一种适用于诊断检查的组合物及其制备试剂盒。本发明还涉及制备上述组合物的方法和设备。
• Pharmaceutical combination comprising adenosine A1 receptor antagonists and radiocontrast media
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1870093A1

  公开（公告）日：2007-12-26

  The present invention relates to pharmaceutical combinations comprising a therapeutically effective amount of at least one selective adenosine A1 antagonist combined with at least one radiocontrast media. The invention also relates to the use of said combinations in the manufacture of a medicament for the treatment of radiocontrast media induced nephropathy. Furthermore, the invention is relating to a kit comprising a single dosage form of said combination of at least one adenosine A1 antagonist and at least one radiocontrast media.

  本发明涉及由治疗有效量的至少一种选择性腺苷 A1 拮抗剂与至少一种放射性造影剂组合而成的药物组合物。本发明还涉及使用所述组合物制造治疗放射性造影剂诱发的肾病的药物。此外，本发明还涉及一种试剂盒，该试剂盒包含上述至少一种腺苷 A1 拮抗剂和至少一种放射造影剂组合的单一剂型。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。